Publication | Closed Access

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

Autoimmune DiseaseMedicineImmunologyNeurological ProgressAutoimmunityT Cell ImmunityCd4 T Cell ResponsesNeurologyAutoantibodiesMultiple SclerosisImmunologic DiseaseImmunotherapyNeuroimmunologyNon-encephalitogenic Type 2Altered Peptide Ligand